格隆汇11月18日丨光弘科技(300735.SZ)在互动平台表示，公司是专业的EMS（电子制造服务）企业， 并未直接从事PCB的生产制造。PCB是公司业务不可或缺的原材料，将作为电子产品基石的PCB和各类 电子元件通过SMT技术贴装结合是公司业务最重要的组成部分。 ...

Financial Data and Key Metrics Changes - Net sales for Q1 fiscal 2026 were $366 million, a 2% decline compared to Q1 fiscal 2025 [5][10] - Gross margin rate improved to 7.9%, a 160 basis point increase from 6.3% in the same period last year [10] - Adjusted income for Q1 was $17.5 million, or 4.8% of net sales, compared to $12.6 million, or 3.4% of net sales last year [11][12] - Adjusted net income was $12.3 million, or $0.49 per diluted share, up from $5.5 million, or $0.22 per diluted share last year [12][13] - Cash and cash equivalents at the end of Q1 were $75.7 million, with cash generated from operations at $8.1 million [13][15] Business Line Data and Key Metrics Changes - Medical sales were $102 million, up 13% year-over-year, accounting for 28% of total revenue [5][6] - Automotive sales were $164 million, down 10% year-over-year, representing 45% of total sales [7] - Industrial sales totaled $100 million, a 1% decrease compared to Q1 last year, making up 27% of total sales [7][8] Market Data and Key Metrics Changes - Medical sales growth was driven by strong performance in North America, Asia, and Europe [5][6] - Automotive sales decline was primarily due to lower sales in North America and Asia, partially offset by growth in Europe [7] - Industrial business saw a decline in North America due to softening demand for HVAC, while Asia reported strong sales growth [8] Company Strategy and Development Direction - The company aims to expand its capabilities in the medical sector, focusing on higher-level assemblies and finished medical devices [6][18] - A tuck-in acquisition strategy is being pursued to add new end markets and manufacturing capabilities [18] - The company is committed to returning to profitable growth, particularly in the medical space, while managing costs and improving margins [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to profitable top-line growth next year and reiterated guidance for fiscal 2026 [4][16] - The company is monitoring the evolving global tariff landscape and expects to recover tariff costs by passing them on to customers [8][9] - Management highlighted the importance of maintaining a strong balance sheet while preparing for growth [43][44] Other Important Information - Cash conversion days improved to 83 days, representing the lowest level in over three years [13][14] - Capital expenditures in Q1 were $10.6 million, primarily for leasehold improvements and the new facility in Indianapolis [15][16] - The company has $14.8 million remaining on its share repurchase program [15] Q&A Session Summary Question: Will working capital increase as top-line growth resumes? - Management does not expect a significant increase in working capital as they have improved inventory management [21][22] Question: Is the current cash conversion days level stable? - Management aims for cash conversion days to remain in the low 80s as the business grows [23] Question: What are the expectations for EBITDA margins? - Management does not expect a deterioration in EBITDA margins and anticipates improvements as growth resumes [24] Question: What is the focus for potential acquisitions in the medical segment? - The company is exploring acquisitions in the medical CMO space, focusing on new technologies and geographies [28] Question: How does the pipeline of medical projects look for revenue growth? - The company has a strong pipeline of medical projects and expects to close several as the year progresses [37][38] Question: What is the outlook for the automotive segment? - Management anticipates continued pressure in the automotive market but remains strategically focused on high-visibility revenue [41] Question: How is the company balancing organic growth and potential acquisitions? - Management is focused on disciplined capital allocation and will consider acquisitions that enhance their CMO strategy [43][44] Question: What impact does accelerated depreciation have on the company? - Accelerated depreciation is beneficial, particularly regarding interest expense deductions [46]

Financial Data and Key Metrics Changes - Net sales for Q3 totaled $375 million, representing a 10% decline year over year when excluding the divested AT and M business [8][13] - Gross margin rate in Q3 was 7.2%, a 70 basis point decline compared to 7.9% in the same period last year, primarily due to a non-recurring consignment inventory sale [13][14] - Adjusted net income for Q3 was $6.8 million or $0.27 per diluted share, down from $9.8 million or $0.39 per diluted share in the same quarter last year [17] Business Line Data and Key Metrics Changes - Medical segment net sales were $115 million, up 2% year over year, driven by non-recurring consignment inventory sales [8][9] - Automotive segment net sales were $173 million, a 14% decrease year over year, representing 46% of total company sales [10] - Industrial segment net sales were $86 million, down 15% year over year, representing 23% of total company sales [11] Market Data and Key Metrics Changes - Sales in the Medical market increased, while the Automotive and Industrial markets experienced declines [8][10][11] - The automotive business is heavily concentrated in North America and China, with growth noted in Europe due to a new electronic braking platform [10] Company Strategy and Development Direction - The company is focusing on expanding its presence in the medical contract manufacturing organization (CMO) space, with a new manufacturing facility in Indianapolis [6][9] - The strategy includes utilizing cash generated from EMS operations to invest in the medical CMO, with expectations for organic revenue growth over time [6][7] - The company aims to improve its global capacity utilization by closing the Tampa facility and streamlining operations [25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to growth through emerging medical technologies and high-level assemblies [25] - The current tariff environment presents uncertainty, impacting the business and customer demand [23][24] - Management is closely monitoring customer demand and market conditions to navigate the unpredictable environment [23][40] Other Important Information - Cash and cash equivalents at the end of Q3 were $51.4 million, with cash flow from operating activities at $30.9 million [17][19] - The company has $19.3 million remaining on its share repurchase program, having repurchased $3 million worth of shares in Q3 [20] Q&A Session Summary Question: Details about the new facility in Indianapolis - The new facility provides more space for growth in the medical CMO and is leased to minimize upfront costs [28][30] Question: Impact of the existing facility's sale - It is too early to determine the potential value of the existing facility, with a transition period of two to three years expected [32] Question: Trends in open orders or backlog - The medical vertical saw the greatest increase in open orders, followed by industrial and automotive [34] Question: Orders pulled into March due to tariffs - Management is uncertain if orders were pulled forward due to tariffs but is monitoring customer feedback [38] Question: Operating expenses outlook - SG&A expenses are expected to rise in FY 2026 as investments are needed for growth [43] Question: Impact of the Tampa facility closure on gross margin - Some gross margin improvement is expected from the Tampa closure, but pressures from tariffs remain [67]